A Form 4 filed on August 10, 2026 disclosed that Tal Zvi Zaks, a director of Teva Pharmaceutical Industries Ltd. (TEVA), sold 17 Ordinary Shares on August 5, 2026.

Key Highlights

  • Reporting person: Tal Zvi Zaks, identified as a Director of Teva Pharmaceutical Industries Ltd.
  • Transaction: 17 Ordinary Shares disposed of (transaction code S) on August 5, 2026.
  • Price: Shares were sold at $34.8655 per share, according to the filing.
  • Post-transaction ownership: Zaks directly held 73,247 Ordinary Shares following the reported transaction.
  • Share structure note: The filing states that Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Director Share Sale Details for Teva Pharmaceutical Industries

According to the filing, Tal Zvi Zaks, listed as a Director at Teva Pharmaceutical Industries Ltd., disposed of 17 Ordinary Shares on August 5, 2026, at a price of $34.8655 per share. The transaction was reported under transaction code S in Table I of the Form 4, indicating an open-market sale of non-derivative securities held directly.

Following the reported transaction, the filing discloses that Zaks beneficially owned 73,247 Ordinary Shares on a direct basis. No derivative securities transactions were reported in Table II of the filing. The form was signed by Dov Bergwerk as attorney-in-fact for Tal Zvi Zaks and filed on August 10, 2026.

The filing notes that the Ordinary Shares of Teva Pharmaceutical Industries Ltd. may be represented by American Depositary Shares, with each American Depositary Share currently representing one Ordinary Share. The issuer is identified in the filing as Teva Pharmaceutical Industries Ltd. with the ticker symbol TEVA.

What Was Disclosed

The Form 4 disclosed a sale of 17 Ordinary Shares by Teva director Tal Zvi Zaks on August 5, 2026, at $34.8655 per share, leaving him with a direct beneficial ownership of 73,247 Ordinary Shares.